Nimotuzumab (BIOMAb EGFR): India’s Own Monoclonal Antibody

Nimotuzumab is a humanised monoclonal antibody that blocks EGFR, the epidermal growth factor receptor. Cancer cells carrying a lot of EGFR use it to keep dividing. Blocking it aims to turn that signal down so radiotherapy and chemotherapy work harder. In India it is branded BIOMAb EGFR and given by infusion.

The antibody itself is not an Indian discovery. It was developed at the Center of Molecular Immunology in Havana, Cuba, where it was known in the laboratory as h-R3. Biocon licensed it for India, manufactured it here, and launched it in 2006 as BIOMAb EGFR. That launch made it the first novel monoclonal antibody produced in India, which is why it is so often described as India’s own antibody. Biocon states it is approved in India and around twenty other countries.

One practical footnote for anyone reading a pack or an invoice. In March 2024 Eris Lifesciences announced the acquisition of Biocon Biologics’ India branded formulations business, which included its oncology brands. The company named on the carton or the bill may therefore differ from the company named in older articles. The molecule is unchanged.

If your prescription reads BIOMAb, BIOMAb EGFR or nimotuzumab, those are the same medicine. The generic line on the label is the one to trust.

In India, nimotuzumab is approved for squamous cell carcinoma of the head and neck, used together with radiotherapy or chemoradiation rather than on its own. That is the Indian label as of August 2026. Use in brain tumours, nasopharyngeal cancer or other sites is approved only in some other countries, not here.

The approval history is worth knowing, because it explains the confusing search results. India cleared nimotuzumab for head and neck cancer in 2006. Other regulators cleared it for different things: glioma in Cuba and Argentina, nasopharyngeal cancer in China, and orphan-drug status for glioma in the United States and for pancreatic cancer in the European Union. A page written for one of those markets does not describe the Indian position.

Some Indian pharmacy listings show extra cancers against the brand name, including colorectal cancer. Those listings are not the label. If a use outside squamous head and neck cancer is being considered, ask your oncologist to say plainly that it is off-label in India and why they think it is justified in your case.

Within head and neck cancer, being on the label still does not make a patient eligible. What the treating team weighs:

• Histology and site — squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, confirmed on biopsy.
• Stage and intent — the evidence sits in locally advanced disease treated with radical chemoradiation, not in early cancer that surgery or radiotherapy alone can handle.
• Whether full-dose cisplatin is possible — much of the Indian discussion about nimotuzumab involves patients who cannot tolerate standard platinum chemotherapy. Whether it is the right substitute there is still argued about, and it is a decision for the tumour board, not a rule.
• Kidney function, hearing and general fitness — these usually decide the chemotherapy backbone, and the backbone decides where nimotuzumab could fit.
• Previous treatment — what has already been given, and how the cancer responded.

Indian oncologists read the CDSCO-approved label alongside the evidence positions published by bodies such as NCCN, ASCO and ESMO. Whether nimotuzumab belongs in your plan is answered by your oncologist reading your reports.

The evidence is mixed and depends entirely on the setting. A randomised phase 3 trial at Tata Memorial Centre, Mumbai, reported better disease control when nimotuzumab was added to cisplatin chemoradiation for locally advanced disease. A separate phase 3 trial reported at ESMO in October 2025 found no benefit after surgery.

The Tata Memorial study is the one most often quoted in India, and with reason: it was run in Indian patients, in Indian hospitals, with the resource realities Indian oncologists actually face. Patients with locally advanced head and neck cancer were randomly assigned to weekly cisplatin chemoradiation with or without weekly nimotuzumab. Results were presented at the ASCO annual meeting in 2018 and published in 2019, and the nimotuzumab arm showed better disease control. That trial is why the drug is discussed at all in Indian head and neck practice.

The counterweight arrived in October 2025. The IHN01 trial, presented at the ESMO Congress in Berlin, randomised 422 patients who had already undergone surgery for stage III or IV head and neck squamous cell carcinoma to weekly nimotuzumab or placebo alongside adjuvant cisplatin-based chemoradiotherapy. After a median follow-up of about five years, neither disease-free survival nor overall survival differed significantly between the two arms. The investigators noted that recruitment had been difficult and that platinum-based chemoradiotherapy is a hard treatment to improve on.

Read together, those two trials say something useful and unglamorous. Where nimotuzumab has shown an advantage, it was as part of definitive chemoradiation in locally advanced disease. It has not shown an advantage as an add-on after surgery. Anyone offering you a firmer promise than that is going beyond the published evidence.

Response and benefit are population findings from trial cohorts. They are not a prediction for one patient, and no honest page can tell you whether a named medicine will help you.

Nimotuzumab is often described as the cheaper anti-EGFR option because it is made in India. It is cheaper than importing an equivalent antibody, but it is not a low-cost medicine. Published Indian retail listings for a 50 mg vial have run from roughly ₹54,000 to ₹67,500 across 2023 to 2026.

Two published listings, named and dated. Medindia listed BIOMAb EGFR 50 mg at ₹54,350 per vial, with a price-updated date of 8 July 2023. Tata 1mg listed a 50 mg BIOMAb injection at a maximum retail price of ₹67,500 when checked in August 2026. Both figures are indicative only, as of August 2026. Neither is a CION rate, and neither is what a hospital pharmacy actually pays after procurement discounts.

The vial price is also the least useful number in the calculation. What decides the bill:

• The weekly dose. The 200 mg weekly schedule used in the Indian trials needs several 50 mg vials each week, so one vial price tells you very little.
• The length of the course, which normally tracks the radiotherapy schedule rather than a fixed number of doses.
• Day-care, nursing, premedication and monitoring charges, which are billed separately from the drug.
• Everything else in the plan — radiotherapy, cisplatin, scans, feeding support and dental work before radiation often add up to more than the antibody does.
• Cover — whether your insurance policy, or a state scheme such as Aarogyasri, includes the drug at all, and at what ceiling.

Comparing list prices with cetuximab, the other anti-EGFR antibody used in head and neck cancer, tends to mislead. Cetuximab is dosed by body surface area while nimotuzumab uses a flat weekly dose, the vial sizes differ, and hospitals negotiate their own procurement rates. A written, itemised estimate from the treating hospital’s billing desk answers the question that a price listing cannot.

Because nimotuzumab is a cold-chain biological, stored between 2°C and 8°C, it is fair to ask a hospital pharmacy how a vial was transported and stored. On reading the paperwork itself, see Reading Your Prescription: What the Drug Name and Dose Mean.

Nimotuzumab is generally better tolerated than other anti-EGFR antibodies. The severe acne-like rash that limits cetuximab is reported far less often. The commonest problems are infusion-related: chills, fever, nausea, flushing and swings in blood pressure. Most of what a patient feels during treatment comes from the radiation and cisplatin.

There is a reasonably well-understood explanation for the skin difference. Nimotuzumab binds EGFR less tightly than cetuximab does, and needs to attach with both of its arms at once to stay put. That happens readily on cells crowded with EGFR, which describes many tumour cells, and much less readily on normal skin and kidney cells, which carry far less. This bivalent-binding requirement has been described in peer-reviewed studies of the antibody, and it is the standard explanation offered for the lower rates of severe rash and of low magnesium seen with nimotuzumab.

Better tolerated is not the same as harmless. Tell the treating team promptly about:

• Breathlessness, wheeze, chest tightness, or swelling of the face, lips or tongue during or shortly after an infusion — alert the day-care nursing staff at once; if you are already home, go to the nearest emergency department.
• Fever with chills in the hours after a dose.
• A rash that blisters, spreads or becomes painful, rather than the mild dryness many patients get.
• Mouth or throat pain that stops you eating or drinking — usually radiation mucositis, but it needs assessment because it is the main driver of weight loss in this treatment.
• Persistent vomiting, reduced urine output, ringing in the ears or new hearing loss — more often cisplatin than nimotuzumab, and worth reporting the same day.

Almost every patient on nimotuzumab is also having radiotherapy and cisplatin, so separating which drug caused what is genuinely difficult and is a job for the treating team. Tell any other doctor treating you — a dentist above all, before any extraction during or after head and neck radiation — exactly what you are receiving.

This is an overview, not a home-management guide. Symptoms during chemoradiation are assessed by the team running the treatment.